PMID- 24929023
OWN - NLM
STAT- MEDLINE
DCOM- 20150409
LR  - 20220318
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 21
IP  - 2
DP  - 2014 Aug
TI  - Therapeutic efficacy of infused molecular hydrogen in saline on rheumatoid 
      arthritis: a randomized, double-blind, placebo-controlled pilot study.
PG  - 468-73
LID - S1567-5769(14)00212-4 [pii]
LID - 10.1016/j.intimp.2014.06.001 [doi]
AB  - The aim of this study was to demonstrate the safety and efficacy of H2-saline 
      infusion for treatment of rheumatoid arthritis (RA). We conducted a randomized, 
      double-blind, placebo-controlled investigation of the infusion of 1 ppm 
      H2-dissolved saline (H2-saline) in 24 RA patients. Patients were randomized 1:1 
      to receive 500 ml of either H2-saline or placebo-saline, which was drop infused 
      intravenously (DIV) daily for 5 days. The disease activity score in 28 joints 
      (DAS28) was measured at baseline, immediately post infusion, and after 4 weeks. 
      Therapeutic effects of H2-saline on joint inflammation were estimated by 
      measuring serum biomarkers for RA, tumor necrosis factor-alpha (TNFalpha), interleukin-6 
      (IL-6), matrix metalloproteinase-3 (MMP-3), and urinary 8-hydroxydeoxyguanosine 
      (8-OHdG). In the H2-infused group, average DAS28 decreased from 5.18 +/- 1.16 to 
      4.02 +/- 1.25 immediately post infusion and reached 3.74 +/- 1.22 after 4 weeks. No 
      significant decrease in DAS28 was observed in the placebo group throughout the 
      study. IL-6 levels in the H2 group significantly decreased in 4 weeks by 37.3 +/- 
      62.0% compared to baseline, whereas it increased by 33.6 +/- 34.4% in the placebo 
      group. TNFalpha levels did not change remarkably in the H2 or placebo groups in 4 
      weeks post-infusion compared to baseline. The relative ratio of 8-OHdG in the H2 
      group also significantly decreased by 4.7%. After 4 weeks, MMP3 was significantly 
      reduced by 19.2% +/- 24.6% in the H2 group, and increased by 16.9% +/- 50.2% in the 
      placebo group. Drop infusion of H2 safely and effectively reduced RA disease 
      activity.
CI  - Copyright (c) 2014. Published by Elsevier B.V.
FAU - Ishibashi, Toru
AU  - Ishibashi T
AD  - Haradoi Hospital, Department of Rheumatology and Orthopaedic Surgery, 6-40-8 
      Aoba, Higashi-ku, Fukuoka 813-8588, Japan. Electronic address: 
      toruishi@haradoi-hospital.com.
FAU - Sato, Bunpei
AU  - Sato B
AD  - MiZ Company, 16-5 Zengyo 1-chome, Fujisawa, Kanagawa 251-0871, Japan. Electronic 
      address: b_sato@e-miz.co.jp.
FAU - Shibata, Shinji
AU  - Shibata S
AD  - Haradoi Hospital, Department of Rheumatology and Orthopaedic Surgery, 6-40-8 
      Aoba, Higashi-ku, Fukuoka 813-8588, Japan. Electronic address: 
      s_shibata@haradoi-hospital.com.
FAU - Sakai, Takaaki
AU  - Sakai T
AD  - Haradoi Hospital, Department of Cardiology, Japan. Electronic address: 
      sakai@haradoi-hospital.com.
FAU - Hara, Yuichi
AU  - Hara Y
AD  - Haradoi Hospital, Department of Internal Medicine, Japan. Electronic address: 
      hara@eos.ocn.ne.jp.
FAU - Naritomi, Yuji
AU  - Naritomi Y
AD  - Haradoi Hospital, Department of Rheumatology and Orthopaedic Surgery, 6-40-8 
      Aoba, Higashi-ku, Fukuoka 813-8588, Japan. Electronic address: 
      naritomi@haradoi-hospital.com.
FAU - Koyanagi, Samon
AU  - Koyanagi S
AD  - Haradoi Hospital, Department of Cardiology, Japan. Electronic address: 
      info@haradoi-hospital.com.
FAU - Hara, Hiroshi
AU  - Hara H
AD  - Haradoi Hospital, Department of Internal Medicine, Japan. Electronic address: 
      hara@haradoi-hospital.com.
FAU - Nagao, Tetsuhiko
AU  - Nagao T
AD  - Midorino Clinic, 7-26-1 Aoba, Higashi-ku, Fukuoka 813-0025, Japan. Electronic 
      address: wakabanonagao@yahoo.co.jp.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20140611
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 451W47IQ8X (Sodium Chloride)
RN  - 7YNJ3PO35Z (Hydrogen)
RN  - 88847-89-6 (8-Hydroxy-2'-Deoxyguanosine)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - G9481N71RO (Deoxyguanosine)
SB  - IM
MH  - 8-Hydroxy-2'-Deoxyguanosine
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arthritis, Rheumatoid/*drug therapy/metabolism/urine
MH  - Deoxyguanosine/analogs & derivatives/urine
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hydrogen/adverse effects/*therapeutic use
MH  - Inflammation/drug therapy/metabolism/urine
MH  - Interleukin-6/metabolism
MH  - Joints/drug effects/metabolism
MH  - Male
MH  - Matrix Metalloproteinase 3/metabolism
MH  - Middle Aged
MH  - Pilot Projects
MH  - Sodium Chloride/*therapeutic use
MH  - Tumor Necrosis Factor-alpha/metabolism
OTO - NOTNLM
OT  - H(2)-Saline
OT  - IL-6
OT  - MMP-3
OT  - Molecular hydrogen
OT  - Reactive oxygen species
OT  - Rheumatoid arthritis
EDAT- 2014/06/15 06:00
MHDA- 2015/04/10 06:00
CRDT- 2014/06/15 06:00
PHST- 2014/05/06 00:00 [received]
PHST- 2014/05/30 00:00 [revised]
PHST- 2014/06/01 00:00 [accepted]
PHST- 2014/06/15 06:00 [entrez]
PHST- 2014/06/15 06:00 [pubmed]
PHST- 2015/04/10 06:00 [medline]
AID - S1567-5769(14)00212-4 [pii]
AID - 10.1016/j.intimp.2014.06.001 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2014 Aug;21(2):468-73. doi: 10.1016/j.intimp.2014.06.001. 
      Epub 2014 Jun 11.